GlassScriptPhysician profile
Jay D Shah
NPI 1134450737
$100,468.17
in general payments reported to CMS, 2019-2025
29 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $5,784 · 2021: $42K · 2022: $7,644 · 2023: $13K · 2024: $7,730 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $4,846 · Travel and Lodging: $1,270 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,552.25 |
| Food and Beverage | $4,846.01 |
| Travel and Lodging | $1,270.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $81,124.93 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $12,683.92 | 2019-2025 | |
| Painteq LLC | $781.83 | 2021 | |
| Vifor Pharma, INC. | $738.02 | 2019-2024 | Veltassa |
| Janssen Pharmaceuticals, INC | $656.97 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $529.86 | 2019-2025 | Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.28 | 2019-2023 | Jardiance |
| Lantheus Medical Imaging, INC. | $400.22 | 2019-2025 | Definity |
| Abbott Laboratories | $382.53 | 2019-2024 | Cardiomems, Perclose Prostyle |
| Inari Medical, INC. | $381.38 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boston Scientific Corporation | $318.69 | 2019-2024 | Watchman Access System, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $258.11 | 2019-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $253.63 | 2022-2025 | |
| Edwards Lifesciences Corporation | $249.77 | 2022-2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $219.79 | 2022-2025 | Verquvo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $215.09 | 2019-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $198.95 | 2019 | |
| Pfizer INC. | $125.85 | 2019-2025 | |
| Bridgebio Pharma, INC. | $124.46 | 2025 | Attruby |
| Amarin Pharma, INC. | $119.64 | 2019-2022 | |
| Biotronik INC. | $99.32 | 2023 | |
| Alnylam Pharmaceuticals INC. | $43.87 | 2023 | Onpattro |
| Esperion Therapeutics, INC. | $42.87 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $25.57 | 2019 | |
| Scpharmaceuticals INC. | $24.40 | 2024 | |
| Cvrx, INC. | $23.66 | 2024 | Barostim Neo System |
| Cardiva Medical, INC. | $15.27 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| W. L. Gore & Associates, INC. | $13.70 | 2022 | |
| Gilead Sciences, INC. | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.